Slovakia Pharmaceuticals and Healthcare Report Q3 2014

  • July 2014
  • -
  • Business Monitor International
  • -
  • 113 pages

Includes 3 FREE quarterly updates
BMI View:
The Slovakian government is planning to allocate EUR278mn (USD386.7mn) in EU funding to develop healthcare and medical infrastructure in Slovakia over the 2014-2020 period, reports news agency TASR. The government added that after adding contributions from the state budget, the total funds that have been allocated for developing healthcare infrastructure will be EUR300mn (USD417.3mn). The government plans to allocate these funds to projects in large university hospitals and developing integrated outpatient healthcare facilities in the country. Slovakia continues to be an attractive pharmaceutical market for large multi-nationals because it generally offers significant potential as a location for pharmaceutical research.

Headline Expenditure Projections
- Pharmaceuticals: EUR1.67bn (USD2.20bn) in 2013 to EUR1.68bn (USD2.13bn) in 2014; 0.6% in local currency terms and -3.2% in US dollar terms. Figures in line with Q214.
- Healthcare: EUR6.00bn (USD7.92bn) in 2013 to EUR6.07bn (USD7.71bn) in 2014; 1.2% in local currency terms and -2.6% in US dollar terms. Slight revision downward owing to macroeconomic backdrop.

Table Of Contents

Slovakia Pharmaceuticals and Healthcare Report Q3 2014
BMI Industry View . 7
SWOT . 9
Political .... 11
Economic .. 12
Business Environment . 13
Industry Forecast 14
Pharmaceutical Market Forecast .. 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2010-2018) . . 15
Healthcare Market Forecast ... 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018) . 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018) . . 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018) . 18
Prescription Drug Market Forecast ... 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018) . 21
Patented Drug Market Forecast ... 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018) . . 23
Generic Drug .. 24
Table: Members Of GENAS, 2011 26
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018) . . 26
OTC Medicine Market Forecast ... 27
Table: Leading Prescription Medicines In Slovakia, By 2011 Volume . . 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018) 29
Pharmaceutical Trade Forecast ... 30
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2012-2018) . . 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2012-2018) 32
Other Healthcare Data 33
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts 35
Table: Slovakia - GDP By Expenditure . . 39
Industry Risk Reward Ratings 40
Central And Eastern Europe Risk/Reward Ratings .... 40
Slovakia Risk/Reward Ratings . 47
Rewards .. 47
Risks .. 47
Market Overview . 50
Industry Trends And Developments 51
Epidemiology .... 51
Table: Main Causes Of Mortality And Morbidity In Slovakia . . 52
Communicable Diseases 52
Healthcare Sector ... 53
Recent Healthcare Sector Developments .... 54
Health Insurance 56
Private Health Insurance .... 57
Recent Health Insurance Developments 58
Research And Development ... 60
Table: Members Of BITCET, 2011 61
Table: Members Of SLOVBIOTECH, 2010 62
Clinical Trials ... 62
Regulatory Development ... 64
Regulatory Regime ... 64
Pharmaceutical Promotion And Advertising . 65
Marketing Authorisation Regime . 66
Intellectual Property Regime . 67
Pricing Regime ... 68
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 69
Reimbursement Regime ... 70
Competitive Landscape 74
Pharmaceutical Industry . 74
Table: Registered Pharmaceutical Manufacturers . 74
Table: Members Of SAFS, 2012 75
Pharmaceutical Distribution . 76
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated) . 76
Pharmaceutical Retail 77
Company Profile .. 79
Roche .. 79
Biotika . 81
HBM Pharma . 84
Imuna Pharma 87
GlaxoSmithKline .. 89
Sanofi .. 91
Pfizer .. 94
Novartis .... 96
Merck and Co .... 98
Zentiva (Sanofi) .. 100
Demographic Forecast .... 103
Demographic Outlook .... 103
Table: Slovakia's Population By Age Group, 1990-2020 ('000) 104
Table: Slovakia's Population By Age Group, 1990-2020 (% of total) 105
Table: Slovakia's Key Population Ratios, 1990-2020 . 106
Table: Slovakia's Rural And Urban Population, 1990-2020 106
Glossary ... 107
Methodology . 109
Pharmaceutical Expenditure Forecast Model .. 109
Healthcare Expenditure Forecast Model .... 109
Notes On Methodology .. 110
Risk/Reward Ratings Methodology . 111
Ratings Overview ... 112
Table: Pharmaceutical Risk/Reward Ratings Indicators . 112
Indicator Weightings .... 113

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • February 2015
  • by Global Data

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 Summary Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, ...

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research study provides an in-depth analysis and forecast of selected areas of the global healthcare acquired infections (HAI) market. The report offers forecasts by treatment segment and type ...

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

  • $ 6 000
  • Industry report
  • April 2015
  • by Frost & Sullivan

Executive Summary Need for Effective Working Capital Management •Decreasing profitability •Fizzling innovation model •Access to new markets •Price premium pressure Key Trends •The analysis of ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.